<DOC>
	<DOCNO>NCT00373490</DOCNO>
	<brief_summary>This clinical study evaluate safety pharmacokinetics overseas determine maximum tolerate dose ( MTD ) MK-0683 ( vorinostat ) Japanese patient population solid tumor .</brief_summary>
	<brief_title>A Study Oral Suberoylanilide Hydroxamic Acid ( Vorinostat ) Patients With Solid Tumors ( 0683-048 )</brief_title>
	<detailed_description />
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Patients histologically cytologically diagnose solid tumor standard therapy available malignancy refractory standard therapy Patients history immunotherapy , radiotherapy , surgery , chemotherapy previous 4 week Any uncontrolled concomitant illness Pregnant breastfeed Serious drug food allergy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>